Abstract:Chemodynamic therapy as a novel type of chemotherapies can damage the DNA structures and induce cell apoptosis and immunogenic cell death (ICD) through generating reactive oxygen species (ROS) to aggravate oxidative stress. Nonetheless, as an intrinsic antioxidative response of tumor cells, the expression of glutathione (GSH) can be upregulated to maintain the cellular redox balance and protect the tumor cells from ROS-mediated damage. In this context, it is feasibly to simultaneous boost ROS generation and GSH depletion in tumor cells, however, the precise delivery and release of GSH scavengers at specitic subcellular sites is of great importance. Herein, we propose a GSH-responsive mesoporous organosilica nanoparticles (MONs)-based nanomedicine MON-CA-TPP@HA through sequentially covalently attaching Triphenylphosphine (TPP) and electrostatic coating hyaluronic acid (HA) onto the surface of cinnamaldehyde (CA) loaded MONs, known as MON-CA-TPP@HA, which has been demonstrated to be an extremely effective therapeutic strategy for cancer treatment through inducing ICD and apoptosis of breast cancer cells. Systematic in vitro experimental results clearly revealed that the nanomedicines can actively target the tumor cells with the help of HA, subsequently entering the tumor cells, and precisely binding with the mitochondria through TPP residues. Upon the cleavage of the disulfide bond in the MONs triggered by over-expressed GSH within tumor, the CA molecules can be released and induce the excessive ROS in situ surrounding the mitochondria to activate oxidative stress to induce apoptosis and ICD of breast cancer cells. The results in vivo experiments confirm that the MON-CA-TPP@HA nanomedicine can effectively promote DCs maturation, CD 8+ T cells activation, and improve the ratio of M1/M2 macrophages which improve tumor immunosuppressive microenvironment. It is thus believed that the current nanomedicines have paved a new way for the future cancer therapy.

Glutathione-Depleting Nanomedicines for Synergistic Cancer Therapy

Glutathione-responsive and -exhausting metal nanomedicines for robust synergistic cancer therapy

Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy

Glutathione-mediated nanomedicines for cancer diagnosis and therapy

Lenvatinib-zinc Phthalocyanine Conjugates As Potential Agents for Enhancing Synergistic Therapy of Multidrug-Resistant Cancer by Glutathione Depletion

Engineering nanomedicine for glutathione depletion-augmented cancer therapy

Intracellular Restructured Reduced Glutathione-Responsive Peptide Nanofibers for Synergetic Tumor Chemotherapy

Cellular defense system-destroying nanoparticles as a platform for enhanced chemotherapy against drug-resistant cancer

GSH-responsive Prodrug-Based Nanodrugs for Augmenting Chemo-Photodynamic Synergistic Therapy Against Tumors

Peroxidase-like Active Nanomedicine with Dual Glutathione Depletion Property to Restore Oxaliplatin Chemosensitivity and Promote Programmed Cell Death

Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy.

Glutathione/Glucose-Depleting Nanoparticles with NO Generation for Ferroptosis/Starvation/NO-Induced Cancer Therapy

Glutathione-depleting Polyprodrug Nanoparticle for Enhanced Photodynamic Therapy and Cascaded Locoregional Chemotherapy

Biodegradable Nanotherapeutic with Simultaneously GSH Depletion and H2O2 Supplying for Enhanced Synergistic Chemotherapy/chemodynamic Therapy

Specific disruption of glutathione-defense system with activatable single molecule-assembled nanoprodrug for boosted photodynamic/chemotherapy eradication of drug-resistant tumors

Glutathione-sensitive Mesoporous Nanoparticles Loaded with Cinnamaldehyde for Chemodynamic and Immunological Therapy of Cancer

Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery.

Nanocatalytic Theranostics with Glutathione Depletion and Enhanced Reactive Oxygen Species Generation for Efficient Cancer Therapy

Self‐Reliant Nanomedicine with Long‐Lasting Glutathione Depletion Ability Disrupts Adaptive Redox Homeostasis and Suppresses Cancer Stem Cells

Tumor-specific carrier-free nanodrugs with GSH depletion and enhanced ROS generation for endogenous synergistic anti-tumor by a chemotherapy-photodynamic therapy

Targeting Glutathione Metabolism: Partner in Crime in Anticancer Therapy